A novel inhalable form of rifapentine

Journal of Pharmaceutical Sciences

Volumn 103, Issue 5, 2014, Pages 1411-1421

  Chan, John G Y ^a   Duke, Colin C ^b   Ong, Hui Xin ^a   Chan, Joseph C Y ^a   Tyne, Anneliese S ^a,c   Chan, Hak Kim ^b   Britton, Warwick J ^c   Young, Paul M ^a   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CENTENARY INSTITUTE   (Australia)

Author keywords

aerosols; crystallization; FTIR; HPLC; NMR; pulmonary; thermal analysis; X ray powder diffractometry

Indexed keywords

QUINONE DERIVATIVE; RIFAPENTINE; AEROSOL; POWDER; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AEROSOL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; CRYSTALLIZATION; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRY POWDER; EPITHELIUM CELL; HUMIDITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG ALVEOLUS MACROPHAGE; LUNG PARENCHYMA; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOISTURE; MOLECULAR WEIGHT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; STORAGE TEMPERATURE; X RAY POWDER DIFFRACTION; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; DRY POWDER INHALER; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; POWDER; PROCEDURES;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIBIOTICS, ANTITUBERCULAR; CELL LINE; DRY POWDER INHALERS; HUMANS; LUNG; MACROPHAGES, ALVEOLAR; MYCOBACTERIUM TUBERCULOSIS; PARTICLE SIZE; POWDERS; RIFAMPIN;

EID: 84898015823     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23911     Document Type: Article

References (34)

1. Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sanchez MS, Porco TC, Borgdorff MW,. 2006. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 3 (8): e273.
2. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL,. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4 (12): e344.
3. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL,. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 180 (11): 1151-1157.
4. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE,. 2012. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 91 (5): 881-888.
5. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW,. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the tuberculosis trials consortium. J Infect Dis 206 (7): 1030-1040.
6. Temple ME, Nahata MC,. 1999. Rifapentine: Its role in the treatment of tuberculosis. Ann Pharmacother 33 (11): 1203-1210.
7. Coowanitwong I, Arya V, Kulvanich P, Hochhaus G,. 2008. Slow release formulations of inhaled rifampin. AAPS J 10 (2): 342-348.
8. Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E,. 2013. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: A new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother 57 (6): 2613-2619.
9. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D,. 2007. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 51 (8): 2830-2836.
10. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A,. 2007. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 32 (2): 140-150.
11. Son YJ, McConville JT,. 2011. A new respirable form of rifampicin. Eur J Pharm Biopharm 78 (3): 366-376.
12. Son YJ, McConville JT,. 2012. Preparation of sustained release rifampicin microparticles for inhalation. J Pharm Pharmacol 64 (9): 1291-1302.
13. Verma RK, Kaur J, Kumar K, Yadav AB, Misra A,. 2008. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 52 (9): 3195-3201.
14. Gonzalez-Juarrero M, Woolhiser LK, Brooks E, DeGroote MA, Lenaerts AJ,. 2012. Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Antimicrob Agents Chemother 56 (7): 3957-3959.
15. Hickey AJ, Misra A, Fourie PB,. 2013. Dry powder antibiotic aerosol product development: Inhaled therapy for tuberculosis. J Pharm Sci 102 (11): 3900-3907.
16. Mitchison DA, Fourie PB,. 2010. The near future: Improving the activity of rifamycins and pyrazinamide. Tuberculosis 90 (3): 177-181.
17. Lemke TL,. 2008. Section 5: Chemotherapeutic agents. In Foye's principles of medicinal chemistry;, Lemke TL, Williams DA, Eds. 6th ed.: Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, United States, p 1133.
18. Zhou K, Li J, Luo JH, Jin Y,. 2012. Crystal growth, structure and morphology of rifapentine methanol solvate. Chinese J Chem Eng 20 (3): 602-607.
19. Zhou K, Li J, Zheng DS,. 2010. Growth, characterization and crystal structure analysis of rifapentine. J Mol Struct 983 (1-3): 27-31.
20. Lee HS, Shin HC, Han SS, Roh JK,. 1992. High-performance liquid chromatographic determination of rifapentine in serum using column switching. J Chromatogr 574 (1): 175-178.
21. Taneja NK, Tyagi JS,. 2007. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovisBCG and Mycobacterium smegmatis. J Antimicrob Chemother 60 (2): 288-293.
22. Krombach F, Munzing S, Allmeling AM, Gerlach JT, Behr J, Dorger M,. 1997. Cell size of alveolar macrophages: An interspecies comparison. Environ Health Perspect 105 Suppl 5: 1261-1263.
23. Botha A, Strydom CA,. 2003. DTA and FT-IR analysis of the rehydration of basic magnesium carbonate. J Therm Anal Calorim 71 (3): 987-995.
24. Prasad B, Bhutani H, Singh S,. 2006. Study of the interaction between rifapentine and isoniazid under acid conditions. J Pharm Biomed Anal 41 (4): 1438-1441.
25. Dhumal RS, Biradar SV, Paradkar AR, York P,. 2009. Particle engineering using sonocrystallization: Salbutamol sulphate for pulmonary delivery. Int J Pharm 368 (1-2): 129-137.
26. United States Pharmacopeial Convention. 2008. Aerosols, nasal sprays, metered-dose inhalers and dry powder inhalers. United States Pharmacopeia 31-National Formulary 26. Rockville, Maryland: United States Pharmacopeial Convention Inc.
27. Chan HK, Gonda I,. 1989. Aerodynamic properties of elongated particles of cromoglycic acid. J Aerosol Sci 20 (2): 157.
28. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL,. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56 (8): 4331-4340.
29. Mor N, Simon B, Mezo N, Heifets L,. 1995. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 39 (9): 2073-2077.
30. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ,. 2011. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 52 (9): e194-199.
31. Mizoe T, Ozeki T, Okada H,. 2008. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech 9 (3): 755-761.
32. Rastogi N, Goh KS, Berchel M, Bryskier A,. 2000. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother 46 (4): 565-570.
33. Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, Fourie PB, Misra A,. 2013. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother 57 (2): 1050-1052.
34. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ,. 2001. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm Res 18 (9): 1315-1319.